336 related articles for article (PubMed ID: 24371138)
1. Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression.
Das A; Durrant D; Koka S; Salloum FN; Xi L; Kukreja RC
J Biol Chem; 2014 Feb; 289(7):4145-60. PubMed ID: 24371138
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling.
Das A; Salloum FN; Filippone SM; Durrant DE; Rokosh G; Bolli R; Kukreja RC
Basic Res Cardiol; 2015 May; 110(3):31. PubMed ID: 25911189
[TBL] [Abstract][Full Text] [Related]
3. Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts.
Koka S; Xi L; Kukreja RC
Basic Res Cardiol; 2012 Mar; 107(2):249. PubMed ID: 22311732
[TBL] [Abstract][Full Text] [Related]
4. Alcohol Dehydrogenase Protects against Endoplasmic Reticulum Stress-Induced Myocardial Contractile Dysfunction via Attenuation of Oxidative Stress and Autophagy: Role of PTEN-Akt-mTOR Signaling.
Pang J; Fuller ND; Hu N; Barton LA; Henion JM; Guo R; Chen Y; Ren J
PLoS One; 2016; 11(1):e0147322. PubMed ID: 26807981
[TBL] [Abstract][Full Text] [Related]
5. Lin28a protects against cardiac ischaemia/reperfusion injury in diabetic mice through the insulin-PI3K-mTOR pathway.
Zhang M; Sun D; Li S; Pan X; Zhang X; Zhu D; Li C; Zhang R; Gao E; Wang H
J Cell Mol Med; 2015 Jun; 19(6):1174-82. PubMed ID: 25688987
[TBL] [Abstract][Full Text] [Related]
6. Chronic treatment with novel nanoformulated micelles of rapamycin, Rapatar, protects diabetic heart against ischaemia/reperfusion injury.
Samidurai A; Salloum FN; Durrant D; Chernova OB; Kukreja RC; Das A
Br J Pharmacol; 2017 Dec; 174(24):4771-4784. PubMed ID: 28967097
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin inhibition attenuates myocardial ischaemia-reperfusion injury in hypertrophic heart.
Ma LL; Ma X; Kong FJ; Guo JJ; Shi HT; Zhu JB; Zou YZ; Ge JB
J Cell Mol Med; 2018 Mar; 22(3):1708-1719. PubMed ID: 29314656
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice.
Koka S; Das A; Salloum FN; Kukreja RC
Free Radic Biol Med; 2013 Jul; 60():80-8. PubMed ID: 23385031
[TBL] [Abstract][Full Text] [Related]
9. Cardiac energy dependence on glucose increases metabolites related to glutathione and activates metabolic genes controlled by mechanistic target of rapamycin.
Schisler JC; Grevengoed TJ; Pascual F; Cooper DE; Ellis JM; Paul DS; Willis MS; Patterson C; Jia W; Coleman RA
J Am Heart Assoc; 2015 Feb; 4(2):. PubMed ID: 25713290
[TBL] [Abstract][Full Text] [Related]
10. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways.
Kang S; Chemaly ER; Hajjar RJ; Lebeche D
J Biol Chem; 2011 May; 286(21):18465-73. PubMed ID: 21478152
[TBL] [Abstract][Full Text] [Related]
11. mTOR-STAT3-notch signalling contributes to ALDH2-induced protection against cardiac contractile dysfunction and autophagy under alcoholism.
Ge W; Ren J
J Cell Mol Med; 2012 Mar; 16(3):616-26. PubMed ID: 21609394
[TBL] [Abstract][Full Text] [Related]
12. Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling.
Daniels A; van Bilsen M; Janssen BJ; Brouns AE; Cleutjens JP; Roemen TH; Schaart G; van der Velden J; van der Vusse GJ; van Nieuwenhoven FA
Acta Physiol (Oxf); 2010 Sep; 200(1):11-22. PubMed ID: 20175764
[TBL] [Abstract][Full Text] [Related]
13. Curcumin inhibits high glucose‑induced inflammatory injury in human retinal pigment epithelial cells through the ROS‑PI3K/AKT/mTOR signaling pathway.
Ran Z; Zhang Y; Wen X; Ma J
Mol Med Rep; 2019 Feb; 19(2):1024-1031. PubMed ID: 30569107
[TBL] [Abstract][Full Text] [Related]
14. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice.
Aasum E; Cooper M; Severson DL; Larsen TS
Can J Physiol Pharmacol; 2005 Feb; 83(2):183-90. PubMed ID: 15791292
[TBL] [Abstract][Full Text] [Related]
15. Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function.
Carley AN; Semeniuk LM; Shimoni Y; Aasum E; Larsen TS; Berger JP; Severson DL
Am J Physiol Endocrinol Metab; 2004 Mar; 286(3):E449-55. PubMed ID: 14600074
[TBL] [Abstract][Full Text] [Related]
16. Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy.
Saeedi Saravi SS; Ghazi-Khansari M; Ejtemaei Mehr S; Nobakht M; Mousavi SE; Dehpour AR
World J Gastroenterol; 2016 May; 22(19):4685-94. PubMed ID: 27217700
[TBL] [Abstract][Full Text] [Related]
17. Discordant signaling and autophagy response to fasting in hearts of obese mice: Implications for ischemia tolerance.
Andres AM; Kooren JA; Parker SJ; Tucker KC; Ravindran N; Ito BR; Huang C; Venkatraman V; Van Eyk JE; Gottlieb RA; Mentzer RM
Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H219-28. PubMed ID: 27199111
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of mitochondrial proteins in a mouse model of type 2 diabetes.
Essop MF; Chan WA; Hattingh S
Cardiovasc J Afr; 2011; 22(4):175-8. PubMed ID: 20859605
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI-3 kinase/Akt/mTOR, but not calcineurin signaling, reverses insulin-like growth factor I-induced protection against glucose toxicity in cardiomyocyte contractile function.
Li SY; Fang CX; Aberle NS; Ren BH; Ceylan-Isik AF; Ren J
J Endocrinol; 2005 Sep; 186(3):491-503. PubMed ID: 16135669
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes.
Fraenkel M; Ketzinel-Gilad M; Ariav Y; Pappo O; Karaca M; Castel J; Berthault MF; Magnan C; Cerasi E; Kaiser N; Leibowitz G
Diabetes; 2008 Apr; 57(4):945-57. PubMed ID: 18174523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
